NeuSpera Medical
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $8.9m | Early VC | |
$26.0m | Series B | ||
$12.0m | Series B | ||
$65.0m | Series C | ||
* | N/A | - | |
* | $23.0m Valuation: $325m | Series D | |
Total Funding | €123m |
Recent News about NeuSpera Medical
EditNeuspera is a medical technology startup that specializes in developing innovative solutions for individuals suffering from Urinary Urgency Incontinence (UUI), a symptom of Overactive Bladder (OAB). The company's flagship product is the Neuspera Implantable Sacral Neuromodulation (SNM) System, a minimally invasive device designed to improve bladder control. The system includes an ultra-miniaturized implant and a wearable external transmitter that powers the implant wirelessly.
The company's business model revolves around the sale of these devices to patients through healthcare providers. The implantable device is powered by Neuspera's proprietary Mid-Field Powering technology, which uses the body's natural composition to efficiently focus power to the implant from the external transmitter. This technology offers a less complicated alternative to traditional treatments for UUI, providing patients with a more convenient and comfortable solution.
Neuspera operates in the medical technology market, specifically targeting individuals suffering from UUI. The company's patient-first approach and innovative technology have positioned it as a potential leader in this niche market. Neuspera generates revenue through the sale of its SNM system to healthcare providers, who then offer the treatment to their patients.
Keywords: Medical Technology, Urinary Urgency Incontinence, Overactive Bladder, Implantable Device, Sacral Neuromodulation, Mid-Field Powering Technology, Minimally Invasive, Healthcare Providers, Patient-First Approach, Revenue Generation.